ArticleCureus2024
Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bind: large-scale biological interaction network discovery through knowledge graph-driven machine learning.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundω-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA, C20:5ω3) and docosahexaenoic acid (DHA, C22:6ω3), are widely regarded as cardioprotective. EPA, but not DHA, has been reported to prevent fibrosis in heart failure. The relationship between the ω-3 PUFA fraction in epicardial adipose tissue (EAT) and subcutaneous adipose tissue (SAT) and vascular inflammation in patients with cardiovascular disease remains unclear.
methodsEAT was collected from patients undergoing cardiovascular surgery (n=21, 11 men, 10 women, 70.4±9.0 years old). Fatty acid fractions were measured in serum, SAT, and EAT by gas chromatography, and serum tumor necrosis factor (TNF) α was measured. No patient had taken EPA or DHA supplements.
resultsDHA concentrations were significantly higher in EAT than in SAT (p=0.001); EPA showed no significant difference. The EPA level of EAT correlated with the serum EPA concentration (p=0.009) but did not correlate significantly with serum DHA, α-linolenic acid (ALA, C18:3ω3), or linoleic acid (LA, C18:2ω6) concentrations. The EPA level of EAT showed a strong correlation with docosapentaenoic acid (DPA, C22:5ω3) and the DHA level of EAT (DHA: p<0.001). ALA (r=-0.519, p=0.039) and EPA (r=-0.611, p=0.027) levels of EAT correlated negatively with the serum TNFα concentration. There were no significant differences in EPA in serum, SAT, and EAT between patients with and without atherosclerotic heart disease.
conclusionsAmong ω-3 PUFA fractions in EAT, ALA and EPA were associated with anti-inflammatory effects in patients with cardiovascular disease. It is likely that an increase in serum EPA concentration is needed to increase ω-3 PUFA levels in EAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.